Hello, and welcome to the Ultragenyx Pharmaceutical Incorporated Conference Call. Please note that this call is being recorded. I'd like to hand the call over to Dan Welch, Chairman of the Board. Dan, the floor is yours.
Thank you, Operator. Good morning, ladies and gentlemen, and welcome to the 2024 annual meeting of stockholders of Ultragenyx Pharmaceutical Incorporated. My name is Dan Welch, and I serve as the Chairman of the Board. Other members of the Board are Dr. Deborah Dunsire, Matthew Fust, Dr. Emil Kakkis, Michael Narachi, Dr. Amrit Ray, Dr. Corsee Sanders, and Dr. Shehnaaz Suliman. I'll be presiding over this meeting. At this time, I call the meeting to order. Emil Kakkis, our President and CEO, is present, and he will walk us through the rest of the meeting. Emil?
Thank you, Dan. Joining us today is Karah Parschauer, Executive Vice President and Chief Legal Officer and Corporate Affairs. Karah will act as Secretary of the Meeting and the Inspector of Elections. We are also joined today by Ray Minehan from our independent auditor, Ernst & Young LLP. During the question-and-answer period at the end of the meeting, Ray will be available to answer your questions concerning Ernst & Young's services to the company, including the audit of the company's financial statements. As noted in the notice and proxy statements previously provided to stockholders, the record date for voting at this meeting was the close of business on April 23, 2024. A list of the registered stockholders on the record date is available for inspection during this meeting and can be found at the URL used to access this meeting.
Notice of this stockholder meeting was mailed on or about April 26, 2024, to all stockholders entitled to vote as of that record date, and Broadridge has delivered an affidavit of distribution to show that notice of this meeting was given. The notice and affidavit will be incorporated into the minutes of this meeting. The Secretary will now report on the shares present at this meeting.
Emil, as of the record date, there were 83,133,341 shares of common stock outstanding and entitled to vote. As Inspector of Elections, I can also report that there are at least 78,535,662 shares of common stock represented at this meeting, or approximately 94% of all shares entitled to vote.
Thank you, Karah. Based on the percentage of total shares of the company held by holders of record now present at the meeting, a quorum is present. The meeting is now duly convened for the purposes of transacting business properly before it.
If you've already turned in your Proxy Card, you should not vote again unless you wish to revoke your proxy or change your vote. If you'd like to vote at today's meeting, you will have the opportunity to do so shortly. At this meeting, stockholders will vote on the four proposals described in the Proxy Statement. Proposal number one is the reelection of three directors as Class II Directors. Proposal number two is the approval of our Amended and Restated 2023 Incentive Plan. Proposal number three is the ratification of the selection of Ernst & Young LLP, as Ultragenyx's independent registered public accounting firm for the fiscal year ending December 31, 2024. Proposal number four is an advisory non-binding vote to approve the compensation of the company's named executive officers.
The Board recommends that you vote for each of the three director nominees in the proposal number one and for the proposals numbers two, three, and four. If you have not already voted by proxy, please mark the appropriate box on the screen, which will then be electronically submitted to the Inspector of Elections. The polls are open for each matter to be voted on. The polls are now officially closed. The final vote totals will be published in the current report on Form 8-K that we will file within four business days. The Inspector of Elections will now report the preliminary vote results.
Based on a preliminary tally of votes cast in person and by proxy, I declare that the director nominees named in the Proxy Statement have been elected to hold office until the 2027 Annual Meeting of Stockholders. The Amended and Restated 2023 Incentive Plan has been approved. The selection of Ernst & Young LLP, as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, has been ratified, and the compensation of the company's named executive officers has been approved.
Thank you. Thank you, Karah. There being no further business, this concludes the formal portion of this meeting, and the meeting is now adjourned.
Thank you, Dan. We'll now entertain appropriate questions from stockholders. If there are no questions, then we want to thank you for attending the 2024 annual meeting of stockholders. Goodbye.